References
Lebbé C, Legendre C, Francés C. Kaposi sarcoma in transplantation. Transplant Revs. 2008; 22:252-261
Vallejo G, Romero C, de Vicente J. Incidence and risk factors for cancer after liver transplantation. Crit Rev Oncol Hemat. 2005; 56:87-99
Wasywich C, Croxson M, van Doornum G, Coverdale H, Ruygrok P. Sirolimus for Kaposi’s sarcoma. J Heart Lung Transpl. 2006; 25:726-729
Ettorre GM, Piselli P, Galatioto L, Rendina M, Nudo F, Sforza D DeNovo malignancies following liver transplantation: results from a multicentric study in Central and Southern Italy, 1990−2008. Transplant P. 2013; 45:2729-2732
Rezaee SA, Cunningham C, Davison AJ, Blackbourn DJ. Kaposi’s Sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol. 2006; 87:1781-1804
Barete S, Calvez V, Mouquet C, Barrou B, Kreis H, Dantal J Clinical features and contribution of virological findings to the management of Kaposi sarcoma in organallograft recipients. Arch Dermatol. 2000; 136:1452-1458
Woodle E, Hanaway M, Buell J, Gross T, First M, Trofe J Kaposi’s sarcoma: an analysis of the US and international experiences from the Israel Penn International Transplant Tumor Registry. Transplant Proc. 2001; 33:3660-3661
Fatahzadeh M, Schwartz R. Oral Kaposi’s sarcoma: a review and update. Int J Dermatol. 2013; 52:666-672
Qunibi W, Akhtar M, Ginn E, Smith P. Kaposi’s sarcoma in cyclosporine-induced gingival hyperplasia. Am J Kidney Dis. 1988; 11:349-352
Neville B, Damm D, Allen C, Bouquot J. Oral and Maxillofacial Pathology, 3rd edn. St Louis, Missouri: Saunders Elsevier; 2009
Kafar SY, Howell DN, Gockerman JP. Malignancy after solid organ transplantation: an overview. Oncologist. 2008; 13:769-778
Shepherd FA, Maher E, Cardella C, Cole E, Greig P, Wade J Treatment of Kaposi’s sarcoma after solid organ transplantation. J Clin Oncol. 1997; 15:2371-2377
Ercan Z, Demir M, Merhametsiz O, Yaryar O, Ulas T, Ayli M. Kaposi’s sarcoma in the early post-transplant period in a kidney transplant recipient. Nefrologia. 2013; 33:861-862
Riva G, Luppi M, Barozzi P, Forghieri F, Potenza L. How I treat HHV8/KSHV-related diseases in posttransplant patients. Blood. 2012; 120:4150-4159
Kolhe N, Mamode N, Van Der Walt J, Pattinson J. Regression of post-transplant Kaposi’s sarcoma using sirolimus. Int J Clin Pract. 2006; 60:1509-1512
Babel N, Eibl N, Ulrich C, Bold G, Sefrin A, Hammer M, Rosenberger C, Reinke P. Development of Kaposi’s sarcoma under sirolimus-based immunosuppression and successful treatment with imiquimod. Transpl Infect Dis. 2008; 10:59-62
Boratyńska M, Zmonarski S, Klinger M. Reccurence of Kaposi’s sarcoma after increased exposure to sirolimus. Int Immunopharmacol. 2006; 6:2018-2022
Lebbé C, Euvrard S, Barrou B, Pouteil-Noble C, Garnier J, Glotz D Sirolimus conversion for patients with posttransplant Kaposi’s sarcoma. Am J Transplant. 2006; 6:2164-2168
Aizawa K, Takahari Y, Higashijima N, Serizawa K, Yogo K, Ishizuka N Nicorandil prevents sirolimus-induced production of reactive oxygen species, endothelial dysfunction, and thrombus formation. J Pharamcol Sci. 2015; 127::284-291
Post-transplant kaposi's sarcoma: an unusual presentation and review of clinical presentation, histology and management
From Volume 44, Issue 7, July 2017 | Pages 674-678
Article
Kaposi's sarcoma (KS) is an uncommon, vascular neoplasm associated with Human Herpes Virus 8 (HHV-8). It arises from lymphatic endothelium-derived cells. There are four defined types − the ‘classical’ sporadic type first described by Kaposi, the ‘endemic’ type found in sub-Saharan African populations, ‘HIV/AIDS Associated’ and ‘Iatrogenic’ found in people who are immunosuppressed through medication (such as those seen in post-transplant patients).1 The first Post-Transplant Kaposi's Sarcoma (PT-KS) was noted in 1969 in a kidney-transplant recipient.2 Kaposi's sarcoma can appear in three clinical forms, based upon the distribution of KS in different systems:3
Prior to the AIDS epidemic and the large increase in organ transplantation, KS was rare, comprising around 0.02−0.06% of malignancies.3
PT-KS in the oral cavity classically presents as a painless, macular red patch or swelling.
An unusual case of PT-KS is presented, with pain from bilateral lesions on the palate.
Register now to continue reading
Thank you for visiting Dental Update and reading some of our resources. To read more, please register today. You’ll enjoy the following great benefits:
What's included
- Up to 2 free articles per month
- New content available